Head and neck cancers (HNCs) are the seventh most common tumors worldwide, with an estimated annual burden of 870 000 new cases and 440 000 deaths in 2020.¹ In addition to being a necessary cause of cervical cancer, human papillomavirus (HPV) is a cause of a growing subset of HNC, including oropharyngeal cancer (OPC).² In the US, the incidence of OPC has surpassed cervical cancer and is the most common HPV-related cancer.³ Of concern is that the incidence of HPV-related OPC continues to increase at a rate of 2.8% per year among men in the US.⁴ The proportion of OPC due to HPV has significantly increased over time, with recent publications indicating that more than 80% of OPCs are attributable to HPV infection.⁵ Human papillomavirus types recognized as carcinogens are HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, and as such are considered high-risk HPV types (HR HPV).⁶ Human papillomavirus–16 alone is responsible for 85% to 96% of HPV-positive OPC cases.⁷ Low-risk HPV types (LR HPV), most commonly 6 and 11, are responsible for anogenital and oral warts and recurrent respiratory papillomatosis, a rare and debilitating disease, both of which reduce quality of life.^5,8